+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma

RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma

Epigenetics 8(9): 893-898

Ras-association domain family of genes consist of 10 members (RASSF1-RASSF10), all containing a Ras-association (RA) domain in either the C- or the N-terminus. Several members of this gene family are frequently methylated in common sporadic cancers; however, the role of the RASSF gene family in rare types of cancers, such as bone cancer, has remained largely uninvestigated. In this report, we investigated the methylation status of RASSF1A and RASSF2 in Ewing sarcoma (ES). Quantitative real-time methylation analysis (MethyLight) demonstrated that both genes were frequently methylated in Ewing sarcoma tumors (52.5% and 42.5%, respectively) as well as in ES cell lines and gene expression was upregulated in methylated cell lines after treatment with 5-aza-2'-deoxcytidine. Overexpression of either RASSF1A or RASSF2 reduced colony formation ability of ES cells. RASSF2 methylation correlated with poor overall survival (p = 0.028) and this association was more pronounced in patients under the age of 18 y (p = 0.002). These results suggest that both RASSF1A and RASSF2 are novel epigenetically inactivated tumor suppressor genes in Ewing sarcoma and RASSF2 methylation may have prognostic implications for ES patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333500

Download citation: RISBibTeXText

PMID: 23887284

DOI: 10.4161/epi.25617

Related references

Ewing's sarcoma oncogene structure: a novel prognostic marker?. Journal of Clinical Oncology 16(4): 1241-1243, 1998

BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatric Blood & Cancer 60(1): 35-40, 2013

Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. Journal of Clinical Oncology 18(17): 3108-3114, 2000

DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. Journal of Urology 181(4): 1678-1685, 2009

Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. RadioTherapy and Oncology 10(2): 101-110, 1987

Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Medical and Pediatric Oncology 32(3): 186-195, 1999

Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing's sarcoma. Virchows Archiv 452(2): 157-167, 2007

Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer 109(4): 780-786, 2007

ProGRP is a possible tumor marker for patients with Ewing sarcoma. Biomedical Research 36(4): 273-277, 2016

Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study. Cancer 78(4): 892-900, 1996

Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. Japanese Journal of Clinical Oncology 46(6): 522-528, 2016

Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients. Targeted Oncology 8(4): 253-260, 2014

Protocol for the examination of specimens from pediatric and adult patients with osseous and extraosseous ewing sarcoma family of tumors, including peripheral primitive neuroectodermal tumor and ewing sarcoma. Archives of Pathology & Laboratory Medicine 129(7): 866-873, 2005

Do Patients With High CHA2DS2-VASc Scores Need High Intensity of Anticoagulants After Valve Surgery?. Circulation Journal, 2018

Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 45(8): 2213-2219, 1980